These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 1517557)

  • 1. The clomipramine challenge test in obsessive compulsive disorder.
    Saiz J; Lopez-Ibor JJ; Vinas R; Hernandez M
    Int Clin Psychopharmacol; 1992 Jun; 7 Suppl 1():41-2. PubMed ID: 1517557
    [No Abstract]   [Full Text] [Related]  

  • 2. Prolactin in childhood obsessive-compulsive disorder: clinical correlates and response to clomipramine.
    Hanna GL; McCracken JT; Cantwell DP
    J Am Acad Child Adolesc Psychiatry; 1991 Mar; 30(2):173-8. PubMed ID: 2016218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroendocrine predictors of response to intravenous clomipramine therapy for refractory obsessive-compulsive disorder.
    Mathew SJ; Coplan JD; Perko KA; Goetz RR; de la Neuz M; Hollander E; Liebowitz MR; Fallon BA
    Depress Anxiety; 2001; 14(4):199-208. PubMed ID: 11754126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cortisol and prolactin responses to d-fenfluramine in non-depressed patients with obsessive-compulsive disorder: a comparison with depressed and healthy controls.
    Lucey JV; O'Keane V; Butcher G; Clare AW; Dinan TG
    Br J Psychiatry; 1992 Oct; 161():517-21. PubMed ID: 1393339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pilot study of biological predictors of treatment outcome in obsessive-compulsive disorder.
    Hollander E; Stein DJ; DeCaria CM; Saoud JB; Klein DF; Liebowitz MR
    Biol Psychiatry; 1993 May; 33(10):747-9. PubMed ID: 8353170
    [No Abstract]   [Full Text] [Related]  

  • 6. Corticotropin releasing factor stimulation test in obsessive compulsive disorder.
    Bailly D; Servant D; Dewailly D; Beuscart R; Racadot A; Fossati P; Parquet PJ
    Biol Psychiatry; 1994 Jan; 35(2):143-6. PubMed ID: 8167212
    [No Abstract]   [Full Text] [Related]  

  • 7. Clomipramine versus phenelzine in obsessive-compulsive disorder. A controlled clinical trial.
    Vallejo J; Olivares J; Marcos T; Bulbena A; Menchón JM
    Br J Psychiatry; 1992 Nov; 161():665-70. PubMed ID: 1422616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circadian rhythms of melatonin, cortisol and prolactin in patients with obsessive-compulsive disorder.
    Monteleone P; Catapano F; Del Buono G; Maj M
    Acta Psychiatr Scand; 1994 Jun; 89(6):411-5. PubMed ID: 8085472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioral and biological results.
    Pigott TA; Pato MT; Bernstein SE; Grover GN; Hill JL; Tolliver TJ; Murphy DL
    Arch Gen Psychiatry; 1990 Oct; 47(10):926-32. PubMed ID: 2222131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous clomipramine and obsessive-compulsive disorder.
    Thakur AK; Remillard AJ; Meldrum LH; Gorecki DK
    Can J Psychiatry; 1991 Sep; 36(7):521-4. PubMed ID: 1933762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serotonergic responsivity in obsessive-compulsive disorder. Effects of chronic clomipramine treatment.
    Zohar J; Insel TR; Zohar-Kadouch RC; Hill JL; Murphy DL
    Arch Gen Psychiatry; 1988 Feb; 45(2):167-72. PubMed ID: 3276283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TRH stimulation test in obsessive-compulsive patients.
    Aizenberg D; Hermesh H; Gil-ad I; Munitz H; Tyano S; Laron Z; Weizman A
    Psychiatry Res; 1991 Jul; 38(1):21-6. PubMed ID: 1946831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dexamethasone suppression test and primary obsessional compulsive disorder.
    Vallejo J; Olivares J; Marcos T; Martínez-Osaba MJ; Ribera F; Bulbena A
    Compr Psychiatry; 1988; 29(5):498-502. PubMed ID: 3180759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fenfluramine stimulation of prolactin in obsessive-compulsive disorder.
    Hewlett WA; Vinogradov S; Martin K; Berman S; Csernansky JG
    Psychiatry Res; 1992 Apr; 42(1):81-92. PubMed ID: 1603884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship of plasma clomipramine and N-desmethylclomipramine to response in obsessive-compulsive disorder.
    Mavissakalian M; Jones B; Olson S; Perel JM
    Psychopharmacol Bull; 1990; 26(1):119-22. PubMed ID: 2371366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary free cortisol levels in obsessive-compulsive disorder.
    Gehris TL; Kathol RG; Black DW; Noyes R
    Psychiatry Res; 1990 May; 32(2):151-8. PubMed ID: 2367600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clomipramine in obsessive-compulsive disorder: clinical response and plasma levels.
    Mavissakalian MR; Jones B; Olson S; Perel JM
    J Clin Psychopharmacol; 1990 Aug; 10(4):261-8. PubMed ID: 2286699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dexamethasone suppression tests in patients with obsessive-compulsive disorder.
    Lieberman JA; Kane JM; Sarantakos S; Cole K; Howard A; Borenstein M; Novacenko H; Puig-Antich J
    Am J Psychiatry; 1985 Jun; 142(6):747-51. PubMed ID: 4003598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Seasonal effects in prolactin response to m-chlorophenylpiperazine challenge in obsessive-compulsive disorder.
    Grossman R; Cohen L; Rosen J; DeCaria C; Hollander E
    Biol Psychiatry; 1996 Jun; 39(11):982-5. PubMed ID: 9162213
    [No Abstract]   [Full Text] [Related]  

  • 20. Neuroendocrine and behavioral responses to mCPP in Obsessive-Compulsive Disorder.
    Khanna S; John JP; Reddy LP
    Psychoneuroendocrinology; 2001 Feb; 26(2):209-23. PubMed ID: 11087965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.